{"id":"atm-fog-in-pd","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The exact molecular mechanism is not publicly detailed, but the formulation approach suggests delivery of a neuroactive compound via inhalation to achieve local or systemic effects relevant to Parkinson's pathology. The 'FOG' designation likely refers to a fog or aerosol delivery system intended to optimize bioavailability and brain penetration.","oneSentence":"ATM FOG is a fog inhalation formulation designed to deliver atomoxetine or a related compound directly to the lungs for potential neuroprotective effects in Parkinson's disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:15.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (phase 3)"}]},"trialDetails":[{"nctId":"NCT03651856","phase":"PHASE3","title":"Atomoxetine for Freezing of Gait in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2013-01","conditions":"Parkinson's Disease, Freezing of Gait","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ATM FOG in PD","genericName":"ATM FOG in PD","companyName":"Medical University of South Carolina","companyId":"medical-university-of-south-carolina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATM FOG is a fog inhalation formulation designed to deliver atomoxetine or a related compound directly to the lungs for potential neuroprotective effects in Parkinson's disease. Used for Parkinson's disease (phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}